Current Opinion in Lipidology was launched in 1990. It is part of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of lipidology is divided into six sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Section Editor for this issue.
Frederick J. Raal, MBBCh (cum laude), FRCP, FRCPC, FCP(SA), Cert Endo, MMED, PhD, DSC
Head, Division of Endocrinology & Metabolism Director, Carbohydrate and Lipid Metabolism Research Unit Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Professor Derick Raal is Professor and Head of the Division of Endocrinology and Metabolism at the University of the Witwatersrand, Johannesburg, South Africa. After obtaining his MBBCh degree cum laude in 1981, he obtained his Master of Medicine his PhD in 2000 and his Doctor of Science in 2022. Professor Raal has received numerous postgraduate awards including the TH Bothwell Research Prize, the FJ Milne award, and the University of the Witwatersrand Vice Chancellor's Research Award in 2015.
He is a NRF A-rated scientist, was recognized as a Web of Science highly cited researcher for 2019, 2021 and 2022, and has authored or co-authored over 350 original articles and book chapters and has reviewed for several international journals including the New England Journal of Medicine, the Lancet, Circulation, and Atherosclerosis. He is a committee member of the homozygous FH International Collaborators registry as well as a member of the steering committee of the European Atherosclerosis Society FH Studies Collaboration (EAS FHSC). He is on the Editorial Board of Atherosclerosis, a co-editor for Current Opinion in Lipidology and is a board member of the International Atherosclerosis Society.
Professor Raal is particularly interested in lipids and lipid disorders and has been integrally involved in the management of familial dyslipidaemia, particularly heterozygous and homozygous familial hypercholesterolaemia (FH). The major focus of his research remains the clinical, biochemical, genetic and therapeutic management of this condition and he continues to conduct studies with novel therapies such as PCSK9-inhibitors and ANGPTL3-inhibitors in this patient group.